The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Abstract
The safety of therapeutic bispecific antibodies that use TfR for delivery to the brain can be improved by reducing affinity for TfR and eliminating antibody effector function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Steinberg, G. R., & Kemp, B. E. (2009) · Physiological Reviews · doi:10.1152/physrev.00011.2008 · Cited by 1,637
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Self-citationThe transferrin receptor: role in health and disease
Ponka, P., & Lok, C. N. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00070-9 · Cited by 595
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Receptor‐mediated transcytosis of transferrin across the blood‐brain barrier
Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R., & Fine, R. E. (1987) · Journal of Neuroscience Research · doi:10.1002/jnr.490180206 · Cited by 544
Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.
Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., & Starzyk, R. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4771 · Cited by 402
Pardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358
Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
Self-citationBoado, R. J., Zhang, Y., Zhang, Y., & Pardridge, W. M. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21120 · Cited by 203
Self-citationReceptor-mediated endocytosis of transferrin at the blood-brain barrier
Roberts, R. L., Fine, R. E., & Sandra, A. (1993) · Journal of Cell Science · doi:10.1242/jcs.104.2.521 · Cited by 203
Moos, T., & Morgan, E. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00541.x · Cited by 169
Circolo, A., Garnier, G., Fukuda, W., Wang, X., Hidvegi, T., Szalai, A. J., Briles, D. E., Volanakis, J. E., Wetsel, R. A., & Colten, H. R. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00021-1 · Cited by 166
Transferrin receptors and iron uptake during erythroid cell development
Iacopetta, B. J., Morgan, E. H., & Yeoh, G. C. T. (1982) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(82)90547-8 · Cited by 160
Gosk, S., Vermehren, C., Storm, G., & Moos, T. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000135592.28823.47 · Cited by 160
Boado, R. J., Zhang, Y., Zhang, Y., Xia, C., & Pardridge, W. M. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060349x · Cited by 142
Self-citationKissel, K., Hamm, S., Schulz, M., Vecchi, A., Garlanda, C., & Engelhardt, B. (1998) · Histochemistry and Cell Biology · doi:10.1007/s004180050266 · Cited by 133
Reticulocytes and reticulocyte enumeration
Riley, R. S., Ben‐Ezra, J. M., Goel, R., & Tidwell, A. (2001) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1039 · Cited by 131
Kalaria, R. N., Sromek, S. M., Grahovac, I., & Harik, S. I. (1992) · Brain Research · doi:10.1016/0006-8993(92)91193-i · Cited by 94
The James Blundell Award Lecture 2007: Do we really understand immune red cell destruction?
Garratty, G. (2008) · Transfusion Medicine · doi:10.1111/j.1365-3148.2008.00891.x · Cited by 91
Macromolecular drug transport into the brain using targeted therapy
Lichota, J., Skjørringe, T., Thomsen, L. B., & Moos, T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06544.x · Cited by 81
Paris‐Robidas, S., Émond, V., Tremblay, C., Soulet, D., & Calon, F. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071027 · Cited by 70
Oh, T. H., Markelonis, G. J., ROYAL, G., & Bregman, B. S. (1986) · Developmental Brain Research · doi:10.1016/0165-3806(86)90111-2 · Cited by 58
A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C. W., Mortensen, D. L., Meilandt, W. J., liu, Y., Heise, C., Hoyte, K., Luk, W., Lu, Y., et al. (2013) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 56
Self-citationDeveloping drugs that can cross the blood-brain barrier: applications to Alzheimer's disease
Banks, W. A. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s2 · Cited by 51
Zhou, Q.-H., Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038349 · Cited by 45
Walus, L. R., Pardridge, W. M., Starzyk, R. M., & Friden, P. M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12894-2 · Cited by 41
Therapeutic Antibodies for Brain Disorders
Paul, S. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002620 · Cited by 16
Cited by
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases
Guo, J. L., & Lee, V. M. Y. (2014) · Nature Medicine · doi:10.1038/nm.3457 · Cited by 641
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651
Metadata
- Authors
- Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H., Tong, R. K., Hoyte, K., Luk, W., Lu, Y., Gadkar, K., Prabhu, S., Ordonia, B. A., Nguyen, Q., Lin, Y., Lin, Z., Balazs, M., Scearce-Levie, K., Ernst, J. A., Dennis, M. S., & Watts, R. J.
- Venue
- Science Translational Medicine
- Published
- 2013-05
- Volume
- 5
- Issue
- 183
- Pages
- 183ra57, 1-12
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2162676548
- Cited by
- 268
- References
- 32
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.